Panag Pharma Receives a Repayable $500,000 Contribution from the Atlantic Canada Opportunities Agency (ACOA)
July 11, 2019 10:00 ET
|
Tetra Bio-Pharma Inc
OTTAWA, July 11, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V: TBP) (OTCQB: TBPMF), is pleased to announce that its wholly owned subsidiary Panag Pharma Inc. has...
Tetra Bio-Pharma Comments on Recent Trading Activity at the Request of IIROC
July 05, 2019 17:42 ET
|
Tetra Bio-Pharma Inc
ORLEANS, Ontario, July 05, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") a bio-pharmaceutical multifaceted corporation with its primary focus in cannabinoid‑based...
New Hemp Energy Drink to be offered to consumers in cannabis accessory stores, vapes stores, and kiosks in Canada and the US
June 18, 2019 08:00 ET
|
Tetra Bio-Pharma Inc
OTTAWA, June 18, 2019 (GLOBE NEWSWIRE) -- Tetra Natural Health, a subsidiary of Tetra Bio-Pharma (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced that it has signed an exclusive agreement with...
Tetra Bio-Pharma’s Management Provides Corporate Update Ahead of Annual General Meeting
June 18, 2019 06:30 ET
|
Tetra Bio-Pharma Inc
U.S. granted patent protection for ophthalmic use;U.S. granted patent protection for topical delivery, increased drug solubility and abuse deterrence;U.S. FDA provides positive response on painful dry...
Tetra Bio-Pharma Announces PPP003 Program Update Following Type B Meeting With U.S. FDA
June 17, 2019 06:30 ET
|
Tetra Bio-Pharma Inc
OTTAWA, June 17, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc., (“Tetra” or the “Company”) a leader in cannabinoid-derived drug discovery and development (TSX VENTURE:TBP) (OTCQB:TBPMF) today...
Panag Pharma Completes Phase 3 Trial With Awaye™
June 11, 2019 06:30 ET
|
Tetra Bio-Pharma Inc
OTTAWA, June 11, 2019 (GLOBE NEWSWIRE) -- Panag Pharma Inc., a subsidiary of Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V: TBP) (OTCQB: TBPMF), today announced completion of Panag 001,...
Tetra Bio-Pharma to Present Key Research Findings as Part of Food and Drug Administration (FDA) Public Hearing on CBD
May 30, 2019 06:30 ET
|
Tetra Bio-Pharma Inc
OTTAWA, May 30, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company"), a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), will...
Tetra Bio-Pharma Announces the Retirement of Bernard Lessard and the Appointment of Sabino Di Paola as Chief Financial Officer
May 14, 2019 06:30 ET
|
Tetra Bio-Pharma Inc
OTTAWA, May 14, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company"), a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), today...
Tetra Bio-Pharma’s Recently acquired Wholly Owned Subsidiary Panag Pharma Provides an Update on Recent Activities
May 09, 2019 06:30 ET
|
Tetra Bio-Pharma Inc
OTTAWA, May 09, 2019 (GLOBE NEWSWIRE) -- PANAG Pharma Inc. (PANAG), a wholly owned subsidiary of Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V: TBP) (OTCQB: TBPMF), a bio-pharmaceutical...
Tetra Bio-Pharma’s Subsidiary, Panag Pharma, Obtains Health Canada Authorization to Commence Its First Veterinary Clinical Study
May 02, 2019 19:30 ET
|
Tetra Bio-Pharma Inc
OTTAWA, May 02, 2019 (GLOBE NEWSWIRE) -- Panag Pharma Inc. (Panag), a subsidiary of Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V: TBP) (OTCQB: TBPMF), today announced that its pilot...